Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stapokibart for Perennial Allergic Rhinitis with Asthma (Single-Arm Phase 4 Study)
ChiCTR2500109902Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of stapokibart in perennial rhinitis and asthma, sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Change from baseline in daily total nasal symptom VAS score at Week 16 of treatment. Started Sep 2025; status: recruiting.
02
Drugs
stapokibart
03
Conditions
perennial rhinitisasthma
Beyond the preview
Go deeper on ChiCTR2500109902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109902.